Non‐clozapine antipsychotic combinations for treatment‐resistant schizophrenia
Referencias
Additional references
Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
Alvir J, Lieberman JA. Agranulocytosis: incidence and risk factors. Journal of Clinical Psychiatry 1994;55 Suppl B:137‐8.
Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405‐11. [PUBMED: 10667106]
Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second‐generation antipsychotics in patients with treatment‐resistant schizophrenia: a review and meta‐analysis of randomized trials. American Journal of Psychiatry 2001;158(4):518‐26.
Chan J, Sweeting M. Combination therapy with non‐clozapine atypical antipsychotic medication: a review of current evidence. Journal of Psychopharmacology 2007;21(6):657‐64.
Chwastiak L, Vanderlip E, Katon W. Treating complexity: collaborative care for multiple chronic conditions. International Review of Psychiatry 2014;26(6):638‐47.
Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD006324.pub2]
Correll CU, Gallego JA. Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long‐standing clinical practice. Psychiatric Clinics of North America 2012;35(3):661‐81.
Deeks J. Issues in the selection for meta‐analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25‐28. Cape Town: The Cochrane Collaboration, 2000.
Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623‐9.
Donner A, Klar N. Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971‐80.
Eaton WW, Martins SS, Nestadt G, Bienvenu OJ, Clarke D, Alexandre P. The burden of mental disorders. Epidemiologic Reviews 2008;30(1):1‐14.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315:629‐34.
Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9.
Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7‐10.
Galling B, Roldan A, Rietschel L, Hagi K, Walyzada F, Zheng W, et al. Safety and tolerability of antipsychotic co‐treatment in patients with schizophrenia: results from a systematic review and meta‐analysis of randomized controlled trials. Expert Opinion on Drug Safety 2016;15(5):591‐612.
Global Burden of Disease Study. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;386(9995):743‐800.
Gulliford MC. Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876‐83.
Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoi B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World Journal of Biological Psychiatry 2012;13(5):318‐78.
Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Forstbauer SI, et al. Ziprasidone as an adjuvant for clozapine ‐ or olanzapine ‐ associated medical morbidity in chronic schizophrenia. Human Psychopharmacology: Clinical and Experimental 2009;24(3):225‐32.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60.
Higgins JPT, Green S (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Iasevoli F, Giordano S, Balletta R, Latte G, Formato M, Prinzivalli E, et al. Treatment resistant schizophrenia is associated with the worst community functioning among severely‐ill highly‐disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones. Progress in Neuro‐Psychopharmacology and Biological Psychiatry 2015;65:34‐48.
Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment‐resistant schizophrenic. A double‐blind comparison with chlorpromazine. Archives of General Psychiatry 1988;45(9):789‐96.
Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester‐Blokland E, et al. A multicenter, randomized, double‐blind, placebo‐controlled, 16‐week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. Journal of Clinical Psychiatry 2009;70(10):1348‐57.
Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986.
Kennedy JL, Altar CA, Taylor DL, Degitar I, Hornberger JC. The social and economic burden of treatment‐resistant schizophrenia: a systematic literature review. International Clinical Psychopharmacology 2014;29(2):63‐76.
Leon AC, Mallinckrodt CH, Chuang‐Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry 2006;59(11):1001‐5. [PUBMED: 16905632]
Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2‐3):231‐8. [PUBMED: 15982856]
Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366‐71. [PUBMED: 16199797]
Manu P, Sarpal D, Muir O, Kane JM, Correll CU. When can patients with potentially life‐threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophrenia Research 2012;134(2‐3):180‐6.
Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249‐52.
Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D‐1, D‐2 and serotonin2 pKi values. Journal of Pharmacology and Experimental Therapeutics 1989;251(1):238‐46.
Meltzer HY. Treatment resistant schizophrenia ‐ the role of clozapine. Current Medical Research and Opinion 1997;14(1):1‐20. [DOI: 10.1185/03007999709113338]
Morgan VA, Waterreus A, Jablensky A, Mackinnon A, McGrath JJ, Carr V, et al. People living with psychotic illness in 2010: the second Australian national survey of psychosis. Australian and New Zealand Journal of Psychiatry 2012;46(8):735‐52.
Naheed M, Green B. Focus on clozapine. Current Medical Research Opinion 2001;17(3):223‐9.
Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:799‐812.
Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of InterventionsVersion 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Shim JC, Shin JG, Kelly DL, Jung DU, Seo YS, Liu KH, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic‐induced hyperprolactinemia: a placebo‐controlled trial. American Journal of Psychiatry 2007;164(9):1404‐10.
Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Suzuki T, Remington G, Mulsant BH, Uchida H, Rajji TK, Graff‐Guerrero A, et al. Defining treatment‐resistant schizophrenia and response to antipsychotics: a review and recommendation. Psychiatry Research 2012;197(1‐2):1‐6.
Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area‐wide and organistation‐based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1‐75.
Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El‐Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254‐7.
Young CR, Bowers MB, Mazure CM. Management of the adverse effects of clozapine. Schizophrenia Bulletin 1998;24(3):381‐90.
